Sutro Biopharma (STU:S090) Construction In Progress: €0.00 Mil (As of Mar. 2026)


STU:S090 Sutro Biopharma Inc STU:S090
45 GF Score
Price €6.24
GF Value €2.66
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Construction In Progress?

Sutro Biopharma STU:S090 45 Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:S090 with a GF Score™ of 45/100 and a GF Value™ of €2.66. The stock has 4 warning signs investors should review.

Sutro Biopharma's quarterly construction in progress increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.13 Mil) but then declined from Dec. 2025 (€0.13 Mil) to Mar. 2026 (€0.00 Mil).

Sutro Biopharma's annual construction in progress increased from Dec. 2023 (€0.46 Mil) to Dec. 2024 (€0.48 Mil) but then declined from Dec. 2024 (€0.48 Mil) to Dec. 2025 (€0.13 Mil).

Sutro Biopharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Construction In Progress Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 1.59 0.46 0.48 0.13

Sutro Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.13 0.00
STU:S090
45GF Score
Sutro Biopharma Inc STU:S090
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Sutro Biopharma (STU:S090) has a Construction In Progress of €0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Construction In Progress too high?
Sutro Biopharma's current Construction In Progress is €0.00 Mil. Overall, Sutro Biopharma has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Construction In Progress compare to CCCC and OCGN?
Sutro Biopharma's Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Sutro Biopharma (STU:S090) has a current Construction In Progress of €0.00 Mil. The stock's GF Value™ is €2.66, compared to a current price of €6.24 — trading 134.4% above its estimated fair value. The current Construction In Progress is €0.00 Mil. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Sutro Biopharma (STU:S090), the current Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (STU:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €6.24 is trading 134.4% above its estimated GF Value™ of €2.66.

Key valuation signals for STU:S090:

  • Construction In Progress: €0.00 Mil
  • GF Value™: €2.66 vs. price of €6.24 (134.4% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STU:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USAS090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STU:S090

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.24
Price
€2.66
GF Value